Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4-year follow-up of neonatal acellular pertussis vaccination
ACTRN12614001325695Phase 3Completed
- Sponsor
- Sydney Children's Hospitals Network
- Start
- Oct 2014
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of tetanus toxoid + diphtheria toxoid + acellular pertussis + inactivated poliovirus vaccine and Boostrix Polio in pertussis (2 arms), sponsored by Sydney Children's Hospitals Network. Primary endpoint: Pertussis antibody response before and after 4-year booster. Started Oct 2014; status: completed.
02
Drugs
tetanus toxoid + diphtheria toxoid + acellular pertussis + inactivated poliovirus vaccineBoostrix Polio
03
Conditions
pertussis
Beyond the preview
Go deeper on ACTRN12614001325695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614001325695.